A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports, for the first time, that: Life-extension therapy: MiR-451 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Significance: This study suggests a small molecule-based life extension therapy. MiR-451, by decreasing the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase), it may promote (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity.
Thus, pharmacological formulations encompassing “MiR-451 activators“ can be used to extend the lifespan of an individual.
Citation: Boominathan L, Life-extension therapy: MiR-451 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via upregulation of its target genes, 15/October/2016, 9.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
# Research cooperation
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How MiR-451 decreases the expression of longevity regulator Ribosomal protein S6 kinase 1 (p70S6 Kinase)
Results guaranteed if not refunded